2023年第二版《NCCN肿瘤临床实践指南:非小细胞肺癌》更新解读

Interpretation of the NCCN clinical practice guidelines in oncology for non-small cell lung cancer(version 2.2023)

肺癌是我国发病率及死亡率均居首位的恶性肿瘤。近年来,低剂量螺旋CT在人群中普及应用使得肺结节检出率上升。2023年2月17日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)更新发布了2023年第二版《NCCN肿瘤临床实践指南:非小细胞肺癌》。本文将对新版指南主要更新内容进行解读,并与国内肺癌诊疗指南相比较,为我国临床医务人员诊治肺癌提供新思路。

Lung cancer is the malignancy with the highest incidence and mortality rate in China.In recent years,the popular use of low-dose computed tomography in the population has led to an increase in the detection rate of pulmonary nodules.The National Comprehensive Cancer Network(NCCN)updated and released the NCCN clinical practice guidelines in oncology for non-small cell lung cancer(version 2.2023)on February 17,2023.This article will interpret the main updates of the new guideline and compare it with the domestic lung cancer treatment guidelines,providing new ideas for the diagnosis and treatment of lung cancer for Chinese clinicians.